caretrace.iopowered by▸healthparse
SearchCohort Builder
Tools▾
KOL FinderTerritoriesDrug Compare
AI Query
Browse▾
By stateBy specialty
Pricing
SearchCohort BuilderToolsKOL FinderTerritoriesDrug CompareAI QueryBrowseBy stateBy specialtyPricing
PROVIDER PROFILE · NPI 1396987756

Maria ZarzourM.D

PRACTICEMDACCSee all providers at this practice →
Medical OncologyHouston, TXI
CROSS-REFERENCE

Related data on other Healthparse brands

ProviderScore
OIG/SAM exclusion screening, sanctions history
© 2026 CareTrace
PricingContactPrivacyTerms
MEDICARE UTILIZATION · PART B · 2024
Total beneficiaries
286
Unique beneficiaries
—
Total services
469
Distinct HCPCS
8
Medicare payment
$41K
Peer benchmark
Q1
Q2
Q3
Q4
Q5
Total Medicare services vs. 393 Medical Oncology providers in TX — below median (cohort median 4,999).
REFERRAL NETWORK

Where Maria Zarzour's patients come from & go

Directional shared-patient flow from Medicare claims — who sends patients to this provider (inbound) and where this provider's patients go next (outbound). 4 inbound referrers · 3 outbound destinations.

Receives referrals from
Inbound — who sends patients here
PhysicianPatientsVisits
UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER1201,512
Girish Shroff
Diagnostic Radiology · Houston, TX
1437
Behrang Amini
Diagnostic Radiology · Houston, TX
1342
William Murphy
Diagnostic Radiology · Houston, TX
1133
Refers patients to
Outbound — where patients go next
PhysicianPatientsVisits
UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER74902
Gregory Gladish
Diagnostic Radiology · Houston, TX
1324
John Madewell
Diagnostic Radiology · Houston, TX
1119
Source: CMS Physician Shared Patient Patterns (30-day window, Medicare FFS). Direction = a beneficiary seen by the first provider, then the second, within 30 days; a proxy for referral, not a documented referral. Pairs with fewer than 11 shared beneficiaries are suppressed.
PRESCRIBING · PART D · 2024
Total Rx claims
308
Beneficiaries
—
Total drug cost
$1.1M
Distinct drugs
7
Brand share
23.1%
Top prescribed drugs
Imatinib Mesylate196 claims
Cabozantinib S-Malate29 claims
Prochlorperazine Maleate21 claims
Ondansetron Hcl20 claims
Pazopanib Hcl16 claims
QUALITY · MIPS · 2024
Final MIPS score
84.3
Quality
70.8
Cost
67.6
Improvement activities
40.0
Promoting interop.
100.0
Payment adjustment
0.39%
Group
INDUSTRY PAYMENTS · OPEN PAYMENTS · 2024
Total received
$3K
Payment records
10
By payment type
Honoraria$1K
Travel and Lodging$1K
Food and Beverage$430